Past events
Conference Call & Webcast: Third Quarter and First Nine Months 2021 Financial Results and Business Updates
November 19, 2021
CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the third quarter and first nine months of 2021 on Friday, November 19, 2021. The company hosted a conference call and webcast on the same day at 2:00 p.m. CET / 08:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript and the archived webcast below.
Downloads
Links
9th International mRNA Health Conference
November 09 - 10, 2021
Hybrid event on-site in Berlin, Germany, and online via virtual platform
Conference Call & Webcast: Focus Shift to Second-Generation mRNA Technology
October 12, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
The company hosted a conference call and webcast on the same day at 03:00 p.m. CEST / 09:00 a.m. EST.
Please find the corresponding press release, presentation slides, transcript as well as an archived webcast below.
Downloads
Links
Press Conference: Focus Shift to Second-Generation mRNA Technology (German language)
October 12, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
The company hosted a German speaking press conference on the same day at 02:00 p.m. CEST / 08:00 a.m. EST.
Please find the corresponding press release, presentation slides and archived webcast below.
Downloads
- Press Release
- Presentation (German only)
Links
- Replay Press Conference (German language)
Final Analysis of Phase 2b/3 Clinical Trial for CVnCoV – Webcast & Conference Call
July 1, 2021
On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.
The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.
A replay of the webcast can be found under "Links".
Downloads
Links
Final Analysis of Phase 2b/3 Clinical Trial of CVnCoV – Press Conference in German Language
July 01, 2021
On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.
The company hosted a press conference in German language on Thursday, July 1, 2021, 10:00 a.m. CEST.
The corresponding presentation slides can be found under "Downloads". An replay of the press conference can be found under "Links".
Downloads
- Press Release
- Presentation (German only)
Links
- Replay Webcast (German only)
Annual General Meeting 2021
June 24, 2021
The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer Time. The AGM was held entirely virtually, without physical attendance of shareholders or others with meeting rights. You were not be able to vote during the AGM and your proxy to vote had to be received no later than 5:59 a.m. Central European Summer Time on Tuesday, June 22, 2021.
Update on Phase 2b/3 Clinical Trial for CureVac’s First-Generation COVID-19 Vaccine candidate, CVnCoV – Webcast & Conference Call
June 17, 2021
To provide an update on Phase 2b/3 clinical trial for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, CureVac N.V. (Nasdaq: CVAC) hosted a webcast and conference call on Thursday, June 17, 2021, at 2:00 p.m. CEST / 8:00 a.m. EST.
The corresponding press release, presentation slides and transcript can be found under “Downloads”. An archived webcast can be found under "Links".
Downloads
Links
German Hauptstadtkongress Medizin und Gesundheit 2021
June 16, 2021
Virtual Panel Discussion (German only):
Medizinischer Fortschritt „Made in Germany“: Gewollt, ermöglicht und erreichbar?